Recordati Rare Diseases North America
Hardeep Singh is a seasoned professional in the pharmaceutical and healthcare industry with extensive experience in strategic roles and account management. Currently serving as the Portfolio Strategy Lead for ANZ at Recordati Rare Diseases since August 2022, Hardeep also holds the title of ANZ Franchise Manager for Oncology. Prior to this, Hardeep was the ANZ Business Lead at EUSA Pharma, and a Haematology/Oncology ANZ Key Account Manager from May 2019 to August 2022. Hardeep's career also includes positions at GSK as a Urology Hybrid Sales Representative and Medical Sales Representative, and at Hospira as a Services Coordinator. Hardeep Singh is an alumnus of Monash University.
This person is not in any offices
Recordati Rare Diseases North America
1 followers
Recordati Rare Diseases Inc. (RRD) markets products to treat rare diseases. RRD is a member of the Recordati Group, which includes Recordati S.p.A., Orphan Europe, among other companies around the globe. The Recordati Group, which was established in 1926 currently employs more than 4,000 worldwide. The RRD mission is to reduce the impact of extremely rare and devastating diseases by providing urgently needed therapies. We work side-by-side with rare disease communities to increase awareness, improve diagnosis and expand availability of treatments for people with rare diseases.